STAAR Surgical reported record revenue and a return to profitability in its second-quarter 2026 earnings results [1].
The financial recovery signals a successful expansion of the EVO Plus product line in China and a strategic pivot in the company's global supply chain.
Preliminary net sales guidance for the second quarter of 2026 exceeded $90 million [2], a significant increase from the $44.3 million reported in the second quarter of 2025 [2]. The company also reported earnings per share of $0.40 [3], surpassing the Zacks consensus estimate of $0.32 [3].
Executives detailed a plan to move 100% of product manufacturing for the Chinese market to Switzerland by the end of 2026 [4]. This move is intended to protect profit margins from ongoing trade pressures. Executive VP and CFO Andrews said margins will continue to be impacted by tariffs until the transition to Switzerland is complete [4].
Financial targets for the remainder of the year remain aggressive. The company expects to end 2026 with a cash balance of over $200 million [4]. Additionally, the firm is managing toward a 2026 spending target of $225 million [4].
These results follow an earnings call held on Aug. 12, with the full transcript published on Aug. 19 [5, 6]. The growth was largely driven by the adoption of the EVO Plus in China, which has bolstered the company's top-line performance despite the costs associated with geopolitical trade barriers.
“Preliminary net sales guidance for Q2 2026 exceeds $90,000,000”
STAAR Surgical's shift to Swiss manufacturing represents a strategic decoupling of its supply chain from US-China trade tensions. By relocating production, the company aims to stabilize margins and sustain the growth of its EVO Plus line in one of its most critical markets while maintaining a high liquidity position to fund future operations.
